Joseph Lasaga - Rigel Pharmaceuticals President

RIGL Stock  USD 18.91  0.10  0.53%   

President

Mr. Joseph Lasaga is Senior Vice President Business Development and Alliance Management of the company. He was appointed Vice President, Business Development and Alliance Management in October 2016 and was made Senior Vice President, Business Development and Alliance Management in January 2019. Prior to rejoining Rigel, Mr. Lasaga was Vice President, Business Development and Alliance Management at Galena Biopharma, Inc., where he was responsible for managing corporate and business development strategy and activities. From 2010 until 2014, Mr. Lasaga was Director, and later named Senior Director, Business Development at Nektar Therapeutics, where he led licensing activities, managed key alliances and structured research collaborations. He began his career at Rigel in 1998, working in research before moving into business development, most recently as Associate Director. In that role, he served as the alliance manager for all of Rigel partners, was an integral member of the negotiating team for Rigel outlicensing of fostamatinib to AstraZeneca in early 2010, and managed all other aspects of business development since 2016.
Age 49
Tenure 8 years
Professional MarksMBA
Address 611 Gateway Blvd, South San Francisco, CA, United States, 94080
Phone650 624 1100
Webhttps://www.rigel.com
Lasaga graduated from San Jose State University with a B.S. in Molecular Biology and earned his M.B.A. in Marketing from San Francisco State University.

Rigel Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of 0.0461 % which means that it generated a profit of $0.0461 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.9905) %, meaning that it created substantial loss on money invested by shareholders. Rigel Pharmaceuticals' management efficiency ratios could be used to measure how well Rigel Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is expected to rise to 0.92 this year, although the value of Return On Tangible Assets will most likely fall to (0.25). At this time, Rigel Pharmaceuticals' Fixed Asset Turnover is quite stable compared to the past year. Asset Turnover is expected to rise to 1.05 this year, although the value of Other Current Assets will most likely fall to about 4.3 M.
Rigel Pharmaceuticals currently holds 60.58 M in liabilities. Rigel Pharmaceuticals has a current ratio of 2.29, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Rigel Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 7 records

PRESIDENT Age

Les TariCidara Therapeutics
N/A
Robert LisickiZura Bio Limited
57
Laura NavaltaCidara Therapeutics
Erin MDTerns Pharmaceuticals
53
James DohertyAcumen Pharmaceuticals
56
Kelly CarranzaAcumen Pharmaceuticals
N/A
Jeffrey SteinCidara Therapeutics
69
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California. Rigel Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 165 people. Rigel Pharmaceuticals (RIGL) is traded on NASDAQ Exchange in USA. It is located in 611 Gateway Blvd, South San Francisco, CA, United States, 94080 and employs 147 people. Rigel Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Rigel Pharmaceuticals Leadership Team

Elected by the shareholders, the Rigel Pharmaceuticals' board of directors comprises two types of representatives: Rigel Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rigel. The board's role is to monitor Rigel Pharmaceuticals' management team and ensure that shareholders' interests are well served. Rigel Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rigel Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Esteban Masuda, Senior Vice President - Research
Joseph Lasaga, Senior Vice President - Business Development and Alliance Management
Raymond JD, General VP
Tarek Sallam, Vice Marketing
David Santos, Executive Officer
Dean CPA, Executive CFO
Julie Patel, Senior Resources
Lisa MD, Executive Officer
Wolfgang MD, Ex Officer
Raul Rodriguez, CEO and President Director and Member of Fin. Committee

Rigel Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rigel Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Rigel Pharmaceuticals is a strong investment it is important to analyze Rigel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rigel Pharmaceuticals' future performance. For an informed investment choice regarding Rigel Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rigel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.48)
Earnings Share
0.27
Revenue Per Share
8.979
Quarterly Revenue Growth
0.966
Return On Assets
0.0461
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.